AI in Clinical Trials Market Size is Anticipated to reach USD 11.61 billion by 2035

According to a recently published report by Roots Analysis, the growing adoption of AI solutions in the clinical trials market is driven by their ability to optimize trial design and protocols, enhance data analysis accuracy, and significantly reduce costs and development timelines

AI in Clinical Trials Market Overview

The global AI in clinical trials market size is expected to reach USD 11.61 billion by 2035, growing at a CAGR of 12.7% during the forecast period.

AI in clinical trials encompasses a diverse array of technologies and solutions, including machine learning algorithms, predictive analytics, natural language processing, and generative AI models. These tools are applied across the entire clinical trial lifecycle, from patient recruitment and trial design to real-time monitoring, data analysis, and regulatory submissions. Derived from vast datasets such as electronic health records, genomic data, and historical trial records, AI solutions optimize every stage of drug development. It is important to note that conventional clinical trial practices have led to prolonged timelines, massive costs, low success rates, and challenges in patient recruitment and retention. Further, AI in clinical trials directly addresses these challenges by improving data quality, which increases the probability of success.

Browse 150+ figures and 170+ market data tables spread across 300+ pages and detailed Table of Content on “AI in Clinical Trials Market by Trial Phase, Type of Offering, Deployment Mode, Therapeutic Area, Technology Exposure, End-user, and Geographical Regions: Industry Trends and Global Forecasts, Till 2035” here: https://www.rootsanalysis.com/reports/ai-based-clinical-trial-solutions.html

Market Drivers

Several factors are propelling the growth of the AI in clinical trials market. The conventional drug development process has become increasingly expensive, and time-consuming, with lengthy trial timelines, high failure rates, and enormous costs. AI-powered solutions have emerged as a transformative alternative, offering multiple advantages such as accelerated patient recruitment, optimized trial design, predictive analytics, and real-time data monitoring. Additionally, the rising pressure to bring new therapies to market faster, driven by growing prevalence of chronic diseases, aging populations, and demand for personalized medicine is boosting the adoption of AI technologies. The exponential growth in healthcare data, including electronic health records, genomic information, and real-world evidence, further supports the integration of AI, enabling more intelligent and efficient clinical research.

Market Restraints

While the AI in Clinical Trials market is experiencing robust growth, it faces several challenges. One of the primary restraints is the high implementation cost and complexity associated with AI solutions. Integrating advanced AI systems requires significant investment in technology, infrastructure, and skilled personnel. Moreover, concerns regarding data privacy, security, and regulatory compliance continue to slow down widespread adoption. Additionally, the effectiveness of AI models can be influenced by the quality and diversity of training data, leading to risks of bias and inconsistent performance across different patient populations and therapeutic areas.

Growth Factors

Despite the challenges, several growth factors continue to drive the AI in clinical trials market forward. The increasing demand for faster and more cost-effective drug development is encouraging pharmaceutical companies and CROs to adopt AI technologies. As the global burden of disease rises and the need for innovative treatments grows, AI is becoming essential for improving trial success rates and reducing development timelines. Furthermore, the shift towards precision medicine and adaptive trial designs, along with supportive regulatory initiatives for digital health technologies, is expected to create strong momentum. The rising recognition of AI as a key enabler of efficient, data-driven, and patient-centric clinical research is anticipated to sustain long-term market expansion.

AI in Clinical Trials Market Segments

Based on trial phase, the market is segmented into Phase I, Phase II, and Phase III.

• In the current year, the phase II sub-segment is anticipated to capture nearly 55% of the AI in clinical trials market share.
• The phase III segment is anticipated to show the highest growth potential during the forecast period of over 13.6% annually.

Based on type of offering, the market is segmented into software and services.

• The services sub-segment captures the largest revenue share of more than 45% in AI in clinical trials market, in 2026.
• The software sub-segment is anticipated to be the fastest growing segment in this industry, with annualized rate (CAGR) of 15.0% during the forecast period.

Based on deployment mode, the market is segmented into cloud-based and on-premises.

• The cloud-based sub-segment captures the largest revenue share of around 75% in AI in clinical trials market, in 2026.
• The cloud-based sub-segment is anticipated to be the fastest growing segment in this industry, with annualized rate (CAGR) of 13.3% during the forecast period.

Based on therapeutic area, the market is segmented into oncological disorders, infectious diseases, CNS disorders, metabolic disorders, immunological disorders, cardiovascular disorders, and other disorders.

• The oncological disorders sub-segment captures the largest revenue share of more than 40% in AI in clinical trials market, in 2026.
• The oncological disorders sub-segment is anticipated to be the fastest growing segment in this industry, with annualized rate (CAGR) of 14.6% during the forecast period.

Based on technology exposure, the market is segmented into machine learning, molecular modeling and simulation, deep learning, omics integration, generative model and other technologies.

• The machine learning sub-segment captures the largest revenue share of around 40% in AI in clinical trials market, in 2026.
• The generative model sub-segment is anticipated to be the fastest growing segment in this industry, with annualized rate (CAGR) of 16.1% during the forecast period.

Based on end-user, the market is segmented into biotechnology and pharmaceutical companies, and academic research institutes, and other end-users.

• The biotechnology and pharmaceutical companies sub-segment captures the largest revenue share of more than 75% in AI in clinical trials market, in 2026.
• The biotechnology and pharmaceutical companies sub-segment is anticipated to be the fastest growing segment in this industry, with annualized rate (CAGR) of 13.8% during the forecast period.

Based on the geographical regions, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa

• Asia Pacific dominated the AI in clinical trials market and is likely to account for the largest revenue share of over 40% in 2026.
• The market in Asia-Pacific is expected to grow at a higher CAGR of 13.6% during the forecast period.

Key Companies Profiled

The AI in clinical trials market report also includes detailed profiles of key players (listed below) that offer AI in clinical trials:

• Clarivate
• ConcertAI
• IQVIA
• LabCorp
• Medidata
• Microsoft
• PathAI
• ServiceNow
• Signant Health
• TransPerfect Life Sciences

You Can Download Free Sample PDF Copy of This Report at: https://www.rootsanalysis.com/reports/ai-based-clinical-trial-solutions/request-sample.html

About Roots Analysis

Roots Analysis is a global leader in the market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com